216 related articles for article (PubMed ID: 32862421)
1. Prenatal Tobacco Exposure and Childhood Neurodevelopment among Infants Born Prematurely.
Robbins LS; Blanchard CT; Sinkey RG; Harris SL; Tita AT; Harper LM
Am J Perinatol; 2021 Feb; 38(3):218-223. PubMed ID: 32862421
[TBL] [Abstract][Full Text] [Related]
2. Intrapartum opioid analgesia and childhood neurodevelopmental outcomes among infants born preterm.
Robbins LS; Perez WM; Casey BM; Blanchard CT; Tita AT; Harper LM
Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100372. PubMed ID: 33831589
[TBL] [Abstract][Full Text] [Related]
3. Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth.
Kamyar M; Manuck TA; Stoddard GJ; Varner MW; Clark E
BJOG; 2016 Jun; 123(7):1161-6. PubMed ID: 26036660
[TBL] [Abstract][Full Text] [Related]
4. Risk of neonatal and childhood morbidity among preterm infants exposed to marijuana.
Dotters-Katz SK; Smid MC; Manuck TA; Metz TD
J Matern Fetal Neonatal Med; 2017 Dec; 30(24):2933-2939. PubMed ID: 27921445
[TBL] [Abstract][Full Text] [Related]
5. Maternal obesity and neuroprotective magnesium sulfate.
McPherson J; Smiley S; Stamilio D
Am J Obstet Gynecol; 2015 Oct; 213(4):582.e1-6. PubMed ID: 26116874
[TBL] [Abstract][Full Text] [Related]
6. Childhood neurodevelopment after spontaneous versus indicated preterm birth.
Nuss EE; Spiegelman J; Turitz AL; Gyamfi-Bannerman C
Am J Obstet Gynecol MFM; 2020 May; 2(2):100082. PubMed ID: 33345968
[TBL] [Abstract][Full Text] [Related]
7. Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial.
Crowther CA; Ashwood P; Middleton PF; McPhee A; Tran T; Harding JE;
JAMA; 2023 Aug; 330(7):603-614. PubMed ID: 37581672
[TBL] [Abstract][Full Text] [Related]
8. Genetic Variation, Magnesium Sulfate Exposure, and Adverse Neurodevelopmental Outcomes Following Preterm Birth.
Clark EAS; Weiner SJ; Rouse DJ; Mercer BM; Reddy UM; Iams JD; Wapner RJ; Sorokin Y; Malone FD; O'Sullivan MJ; Peaceman AM; Hankins GDV; Dudley DJ; Caritis SN;
Am J Perinatol; 2018 Aug; 35(10):1012-1022. PubMed ID: 29510423
[TBL] [Abstract][Full Text] [Related]
9. Proximity of magnesium exposure to delivery and neonatal outcomes.
Turitz AL; Too GT; Gyamfi-Bannerman C
Am J Obstet Gynecol; 2016 Oct; 215(4):508.e1-6. PubMed ID: 27177525
[TBL] [Abstract][Full Text] [Related]
10. Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol.
Crowther CA; Middleton PF; Wilkinson D; Ashwood P; Haslam R;
BMC Pregnancy Childbirth; 2013 Apr; 13():91. PubMed ID: 23570677
[TBL] [Abstract][Full Text] [Related]
11. Correlation between initial neonatal and early childhood outcomes following preterm birth.
Manuck TA; Sheng X; Yoder BA; Varner MW
Am J Obstet Gynecol; 2014 May; 210(5):426.e1-9. PubMed ID: 24793722
[TBL] [Abstract][Full Text] [Related]
12. Neurodevelopmental outcomes of preterm infants conceived by assisted reproductive technology.
Roychoudhury S; Lodha A; Synnes A; Abou Mehrem A; Canning R; Banihani R; Beltempo M; Theriault K; Yang J; Shah PS; Soraisham AS; ; ;
Am J Obstet Gynecol; 2021 Sep; 225(3):276.e1-276.e9. PubMed ID: 33798481
[TBL] [Abstract][Full Text] [Related]
13. Preterm premature rupture of membranes at 22-25 weeks' gestation: perinatal and 2-year outcomes within a national population-based study (EPIPAGE-2).
Lorthe E; Torchin H; Delorme P; Ancel PY; Marchand-Martin L; Foix-L'Hélias L; Benhammou V; Gire C; d'Ercole C; Winer N; Sentilhes L; Subtil D; Goffinet F; Kayem G
Am J Obstet Gynecol; 2018 Sep; 219(3):298.e1-298.e14. PubMed ID: 29852153
[TBL] [Abstract][Full Text] [Related]
14. Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes.
McPherson JA; Rouse DJ; Grobman WA; Palatnik A; Stamilio DM
Obstet Gynecol; 2014 Oct; 124(4):749-755. PubMed ID: 25198275
[TBL] [Abstract][Full Text] [Related]
15. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.
Crowther CA; Hiller JE; Doyle LW; Haslam RR;
JAMA; 2003 Nov; 290(20):2669-76. PubMed ID: 14645308
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
Rouse DJ; Hirtz DG; Thom E; Varner MW; Spong CY; Mercer BM; Iams JD; Wapner RJ; Sorokin Y; Alexander JM; Harper M; Thorp JM; Ramin SM; Malone FD; Carpenter M; Miodovnik M; Moawad A; O'Sullivan MJ; Peaceman AM; Hankins GD; Langer O; Caritis SN; Roberts JM;
N Engl J Med; 2008 Aug; 359(9):895-905. PubMed ID: 18753646
[TBL] [Abstract][Full Text] [Related]
17. Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis.
Drassinower D; Friedman AM; Običan SG; Levin H; Gyamfi-Bannerman C
BJOG; 2016 Sep; 123(10):1629-35. PubMed ID: 27245741
[TBL] [Abstract][Full Text] [Related]
18. General anesthesia for cesarean delivery and childhood neurodevelopmental and perinatal outcomes: a secondary analysis of a randomized controlled trial.
Robbins LS; Blanchard CT; Biasini FJ; Powell MF; Casey BM; Tita AT; Harper LM
Int J Obstet Anesth; 2021 Feb; 45():34-40. PubMed ID: 33121885
[TBL] [Abstract][Full Text] [Related]
19. Association of Maternal Obesity with Child Cerebral Palsy or Death.
McPherson JA; Smid MC; Smiley S; Stamilio DM
Am J Perinatol; 2017 May; 34(6):563-567. PubMed ID: 27855463
[No Abstract] [Full Text] [Related]
20. Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes.
Faucett AM; Metz TD; DeWitt PE; Gibbs RS
Am J Obstet Gynecol; 2016 Feb; 214(2):287.e1-287.e5. PubMed ID: 26435047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
